Stockpolly
Search
Delisting risk
CRDF · NASDAQ · Biotechnology

Cardiff Oncology (CRDF)

Develops onvansertib for first-line RAS-mutated metastatic colorectal cancer.

$1.03
Pre-market−0.02 (−1.90%)
At close$1.05(+1.94%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000000000
Cost of revenue00001000120000
Gross profit0000−900−110000
111011133131431281310
Research & development8889101010128576
333303404364
Selling & marketing1−20000000000
General & administrative243303404364
Other expenses0000−700−80000
Operating income−11−10−11−13−13−13−14−15−12−8−13−10
111111111110
Interest income111111111110
Other non-operating income0−1−1−1−1−1−1−1−1−1−10
Income before tax−10−9−10−12−12−12−13−14−11−7−12−9
Net income from continuing operations−10−9−10−12−12−12−13−14−11−7−12−9
Net income−10−9−10−12−12−12−13−14−11−7−12−9
EPS, basic−$0.22−$0.21−$0.22−$0.26−$0.25−$0.25−$0.28−$0.21−$0.17−$0.11−$0.18−$0.14
EPS, diluted−$0.22−$0.21−$0.22−$0.26−$0.25−$0.25−$0.28−$0.21−$0.17−$0.11−$0.18−$0.14
Weighted average shares, basic454545454748486767676868
Weighted average shares, diluted454545454748486767676868
EBITDA−11−9−10−12−12−12−13−14−11−7−12−9
Depreciation & amortization000000000000
EBIT−11−9−10−12−12−12−13−14−11−7−12−9